NASDAQ:RVLP RVL Pharmaceuticals (RVLP) Stock Price, News & Analysis → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free RVLP Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.00▼$0.1952-Week Range N/AVolume63.96 million shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice Target$2.50 Stock AnalysisStock Analysis Get RVL Pharmaceuticals alerts: Email Address Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About RVL Pharmaceuticals Stock (NASDAQ:RVLP)RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.Read More Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> RVLP Stock News HeadlinesMarch 2, 2024 | seekingalpha.comRVLPQ RVL Pharmaceuticals plcJanuary 11, 2024 | morningstar.comRVL Pharmaceuticals PLC RVLPQApril 26, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.October 13, 2023 | marketwatch.comRVL Pharmaceuticals Shares Plummet 50% as Subsidiaries File For BankruptcyOctober 12, 2023 | benzinga.comSpecialty Pharma Firm RVL Pharmaceuticals Subsidiaries File for BankruptcyOctober 12, 2023 | markets.businessinsider.comRVL Subsidiaries To Effectuate Change Of Control; RVLP Ordinary Shares Expected To Be CancelledOctober 12, 2023 | finance.yahoo.comRVL Pharmaceuticals Subsidiaries File for BankruptcyOctober 6, 2023 | investorplace.comWhy Is RVL Pharmaceuticals (RVLP) Stock Up 28% Today?April 26, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.August 23, 2023 | finance.yahoo.comUnmasking the Value Trap: A Deep Dive into RVL Pharmaceuticals PLCAugust 23, 2023 | finance.yahoo.comRVL Pharmaceuticals plc to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 21, 2023 | markets.businessinsider.comRVL Pharmaceuticals (RVLP) Gets a Buy from H.C. WainwrightAugust 16, 2023 | benzinga.comCrude Oil Falls Sharply; RVL Pharmaceuticals Shares PlummetAugust 16, 2023 | msn.comRVLP: Second Quarter ResultsAugust 16, 2023 | marketwatch.comRVL Pharmaceuticals Shares Hit New Lows After Stock Sale >RVLPAugust 16, 2023 | msn.comRVL Pharmaceuticals shares fall after pricing $5M stock offeringAugust 16, 2023 | finance.yahoo.comDowngrade: Here's How Analysts See RVL Pharmaceuticals plc (NASDAQ:RVLP) Performing In The Near TermAugust 16, 2023 | finance.yahoo.comRVL Pharmaceuticals plc Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq RulesAugust 15, 2023 | finance.yahoo.comQ2 2023 RVL Pharmaceuticals PLC Earnings CallAugust 14, 2023 | msn.comRVLP: Revenue Dip Prompts Spending ReversalAugust 14, 2023 | finance.yahoo.comRVL Pharmaceuticals plc Reports Second Quarter 2023 Financial Results; Provides Update on Strategic Business ReviewJuly 20, 2023 | finance.yahoo.comInsiders Re-Evaluate Their US$1.6m Stock Purchase As RVL Pharmaceuticals Falls To US$43mJuly 5, 2023 | msn.comRVL Pharma (NASDAQ:RVLP) Rises on Mulling A Strategic TransactionJuly 5, 2023 | benzinga.comRVL Pharmaceuticals shares are trading higher after the company said it has been considering certain strategic alternatives.June 15, 2023 | finance.yahoo.comRVL Pharmaceuticals plc Announces Result of Proposal to Approve a Waiver of Offer Obligations under Rule 9 of the Irish Takeover Rules at Annual General MeetingJune 2, 2023 | finance.yahoo.comShareholders in RVL Pharmaceuticals (NASDAQ:RVLP) are in the red if they invested three years agoMay 13, 2023 | finance.yahoo.comTime To Worry? Analysts Just Downgraded Their RVL Pharmaceuticals plc (NASDAQ:RVLP) OutlookSee More Headlines Receive RVLP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for RVL Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/20/2023Today4/26/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:RVLP CUSIPN/A CIK1739426 Webwww.osmotica.com Phone(908) 809-1300FaxN/AEmployees125Year FoundedN/APrice Target and Rating Average Stock Price Target$2.50 High Stock Price Target$3.00 Low Stock Price Target$2.00 Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$49.72 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.51 per share Price / BookN/AMiscellaneous Outstanding Shares111,410,000Free Float106,504,000Market CapN/A OptionableOptionable BetaN/A 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Brian A. Markison (Age 64)Chairman, President, CEO & Principal Financial Officer Comp: $525kMr. James D. Schaub (Age 41)Executive VP & COO Comp: $367.2kMr. Christopher A. Klein (Age 58)General Counsel & Secretary Comp: $367.2kMr. Michael J. DePetris (Age 46)Principal Accounting Officer Mr. Jarret MillerExecutive Vice President of Human ResourcesKey CompetitorsContext TherapeuticsNASDAQ:CNTXGrifolsNASDAQ:GRFSLAVA TherapeuticsNASDAQ:LVTXMainz BiomedNASDAQ:MYNZNLS PharmaceuticsNASDAQ:NLSPView All CompetitorsInsidersLtd AltchemSold 4,758,899 sharesTotal: $142,766.97 ($0.03/share)Foundation HarsaulSold 3,421,537 sharesTotal: $205,292.22 ($0.06/share) RVLP Stock Analysis - Frequently Asked Questions Should I buy or sell RVL Pharmaceuticals stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for RVL Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" RVLP shares. View RVLP analyst ratings or view top-rated stocks. What is RVL Pharmaceuticals' stock price target for 2024? 1 Wall Street research analysts have issued 1 year price objectives for RVL Pharmaceuticals' shares. Their RVLP share price targets range from $2.00 to $3.00. On average, they predict the company's share price to reach $2.50 in the next year. View analysts price targets for RVLP or view top-rated stocks among Wall Street analysts. When is RVL Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our RVLP earnings forecast. How were RVL Pharmaceuticals' earnings last quarter? RVL Pharmaceuticals plc (NASDAQ:RVLP) announced its quarterly earnings data on Monday, March, 20th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by $0.03. The company had revenue of $9.81 million for the quarter, compared to the consensus estimate of $12.10 million. During the same period in the previous year, the business posted ($0.26) earnings per share. This page (NASDAQ:RVLP) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersFed launches fourth dollar overhaulStansberry ResearchBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressA.I. is a Tidal Wave - Here’s What to BuyChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RVL Pharmaceuticals plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.